BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+3.95%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$9.45B
AUM Growth
+$719M
(+8.2%)
Cap. Flow
+$607M
Cap. Flow
% of AUM
6.42%
Top 10 Holdings %
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21
Top Buys
| 1 |
ACCD
Accolade, Inc. Common Stock
ACCD
|
$53.3M |
| 2 |
ESSA Pharma
EPIX
|
$53M |
| 3 |
Revolution Medicines
RVMD
|
$47.1M |
| 4 |
SILK
Silk Road Medical, Inc. Common Stock
SILK
|
$39.8M |
| 5 |
Becton Dickinson
BDX
|
$32.4M |
Top Sells
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
$100M |
| 2 |
Halozyme
HALO
|
$43.1M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$38.1M |
| 4 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
$33.3M |
| 5 |
Esperion Therapeutics
ESPR
|
$32.2M |
Sector Composition
| 1 | Healthcare | 95.93% |
| 2 | Industrials | 0.88% |
| 3 | Technology | 0.47% |
| 4 | Consumer Discretionary | 0.04% |
| 5 | Financials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Becton Dickinson
BDX
$54.3B
| $112M | 1.19% |
472,489
+136,539
| +41% | +$32.4M |
|
|
27
Esperion Therapeutics
ESPR
$490M
| $112M | 1.18% |
3,989,164
-1,149,287
| -22% | -$32.2M |
|
28
Cigna
CI
$80.2B
| $108M | 1.15% |
448,162
+34,954
| +8% | +$8.45M |
|
29
Scholar Rock
SRRK
$3.3B
| $108M | 1.14% |
2,131,125
-155,526
| -7% | -$7.88M |
|
|
MYOV
30
DELISTED
Myovant Sciences Ltd.
MYOV
| $107M | 1.13% |
5,194,039
+390,000
| +8% | +$8.03M |
|
31
Danaher
DHR
$143B
| $106M | 1.13% |
533,702
-68,418
| -11% | -$13.7M |
|
|
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
| $103M | 1.09% |
543,207
+115,718
| +27% | +$21.9M |
|
33
Jazz Pharmaceuticals
JAZZ
$7.99B
| $90.5M | 0.96% |
550,650
+161,785
| +42% | +$26.6M |
|
34
Boston Scientific
BSX
$159B
| $89.9M | 0.95% |
2,326,787
+116,928
| +5% | +$4.52M |
|
|
AXNX
35
DELISTED
Axonics, Inc. Common Stock
AXNX
| $87.2M | 0.92% |
1,456,274
+287,296
| +25% | +$17.2M |
|
36
Insmed
INSM
$30.3B
| $84.4M | 0.89% |
2,477,166
+860,166
| +53% | +$29.3M |
|
37
Stryker
SYK
$149B
| $83.9M | 0.89% |
344,514
+6,499
| +2% | +$1.58M |
|
38
Centene
CNC
$14.8B
| $82.5M | 0.87% |
1,290,597
+105,550
| +9% | +$6.75M |
|
39
Nektar Therapeutics
NKTR
$543M
| $79.1M | 0.84% |
263,640
+5,889
| +2% | +$1.77M |
|
40
Align Technology
ALGN
$9.59B
| $78M | 0.82% |
143,960
+31,192
| +28% | +$16.9M |
|
41
DexCom
DXCM
$30.9B
| $77.7M | 0.82% |
864,772
+11,544
| +1% | +$1.04M |
|
42
Edwards Lifesciences
EW
$47.7B
| $74.5M | 0.79% |
890,256
+63,338
| +8% | +$5.3M |
|
|
HRC
43
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $73M | 0.77% |
660,628
+8,103
| +1% | +$895K |
|
44
Evolent Health
EVH
$1.11B
| $71.3M | 0.75% |
3,528,547
+379,436
| +12% | +$7.66M |
|
|
ACCD
45
DELISTED
Accolade, Inc. Common Stock
ACCD
| $70.8M | 0.75% |
1,561,121
+1,175,813
| +305% | +$53.3M |
|
46
HCA Healthcare
HCA
$95.4B
| $70.5M | 0.75% |
374,563
+7,519
| +2% | +$1.42M |
|
47
Generation Bio
GBIO
$40.3M
| $68.1M | 0.72% |
239,318
+6,000
| +3% | +$1.71M |
|
48
Hologic
HOLX
$14.7B
| $68M | 0.72% |
913,752
+5,164
| +0.6% | +$384K |
|
49
Relay Therapeutics
RLAY
$709M
| $66.8M | 0.71% |
1,931,344
+521,987
| +37% | +$18M |
|
50
Exelixis
EXEL
$9.95B
| $66.5M | 0.7% |
2,944,500
| – | – |
|